nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A1—hematologic cancer	0.245	0.775	CbGaD
Amantadine—ABCB1—hematologic cancer	0.0712	0.225	CbGaD
Amantadine—SLC22A2—Daunorubicin—hematologic cancer	0.0379	0.103	CbGbCtD
Amantadine—SLC22A2—Cytarabine—hematologic cancer	0.0334	0.0912	CbGbCtD
Amantadine—SLC22A2—Cladribine—hematologic cancer	0.0316	0.0861	CbGbCtD
Amantadine—SLC22A1—Cytarabine—hematologic cancer	0.029	0.0792	CbGbCtD
Amantadine—SLC22A2—Imatinib—hematologic cancer	0.029	0.0792	CbGbCtD
Amantadine—SLC22A1—Cladribine—hematologic cancer	0.0274	0.0748	CbGbCtD
Amantadine—SLC22A1—Imatinib—hematologic cancer	0.0252	0.0688	CbGbCtD
Amantadine—ABCB1—Lenalidomide—hematologic cancer	0.0172	0.0469	CbGbCtD
Amantadine—SLC22A2—Vinblastine—hematologic cancer	0.0161	0.044	CbGbCtD
Amantadine—SLC22A2—Cisplatin—hematologic cancer	0.0148	0.0403	CbGbCtD
Amantadine—ABCB1—Daunorubicin—hematologic cancer	0.0101	0.0275	CbGbCtD
Amantadine—ABCB1—Alitretinoin—hematologic cancer	0.00988	0.027	CbGbCtD
Amantadine—ABCB1—Imatinib—hematologic cancer	0.00773	0.0211	CbGbCtD
Amantadine—ABCB1—Nilotinib—hematologic cancer	0.00702	0.0192	CbGbCtD
Amantadine—ABCB1—Vinorelbine—hematologic cancer	0.00696	0.019	CbGbCtD
Amantadine—ABCB1—Dasatinib—hematologic cancer	0.0062	0.0169	CbGbCtD
Amantadine—ABCB1—Mitoxantrone—hematologic cancer	0.00613	0.0167	CbGbCtD
Amantadine—ABCB1—Betamethasone—hematologic cancer	0.00546	0.0149	CbGbCtD
Amantadine—ABCB1—Gemcitabine—hematologic cancer	0.00541	0.0148	CbGbCtD
Amantadine—ABCB1—Prednisolone—hematologic cancer	0.00539	0.0147	CbGbCtD
Amantadine—ABCB1—Prednisone—hematologic cancer	0.00509	0.0139	CbGbCtD
Amantadine—ABCB1—Irinotecan—hematologic cancer	0.00483	0.0132	CbGbCtD
Amantadine—ABCB1—Vinblastine—hematologic cancer	0.00429	0.0117	CbGbCtD
Amantadine—ABCB1—Vincristine—hematologic cancer	0.00422	0.0115	CbGbCtD
Amantadine—ABCB1—Cisplatin—hematologic cancer	0.00393	0.0107	CbGbCtD
Amantadine—ABCB1—Etoposide—hematologic cancer	0.00386	0.0105	CbGbCtD
Amantadine—ABCB1—Dexamethasone—hematologic cancer	0.00318	0.00867	CbGbCtD
Amantadine—GRIN3B—lung—hematologic cancer	0.00278	0.144	CbGeAlD
Amantadine—ABCB1—Doxorubicin—hematologic cancer	0.00264	0.00719	CbGbCtD
Amantadine—GRIN3B—testis—hematologic cancer	0.00262	0.136	CbGeAlD
Amantadine—ABCB1—Methotrexate—hematologic cancer	0.00255	0.00697	CbGbCtD
Amantadine—GRIN2C—testis—hematologic cancer	0.00126	0.0652	CbGeAlD
Amantadine—GRIN2D—testis—hematologic cancer	0.00117	0.0606	CbGeAlD
Amantadine—GRIN3A—testis—hematologic cancer	0.0011	0.057	CbGeAlD
Amantadine—GRIN2A—testis—hematologic cancer	0.00087	0.045	CbGeAlD
Amantadine—DDC—lung—hematologic cancer	0.000862	0.0446	CbGeAlD
Amantadine—DDC—testis—hematologic cancer	0.000813	0.0421	CbGeAlD
Amantadine—MAOB—hematopoietic system—hematologic cancer	0.000763	0.0395	CbGeAlD
Amantadine—DDC—lymph node—hematologic cancer	0.000589	0.0305	CbGeAlD
Amantadine—SLC22A1—blood—hematologic cancer	0.000572	0.0296	CbGeAlD
Amantadine—SIGMAR1—blood—hematologic cancer	0.000528	0.0273	CbGeAlD
Amantadine—SIGMAR1—bone marrow—hematologic cancer	0.000511	0.0264	CbGeAlD
Amantadine—MAOB—blood—hematologic cancer	0.000506	0.0262	CbGeAlD
Amantadine—SIGMAR1—lung—hematologic cancer	0.000463	0.024	CbGeAlD
Amantadine—MAOB—lung—hematologic cancer	0.000443	0.0229	CbGeAlD
Amantadine—SIGMAR1—testis—hematologic cancer	0.000437	0.0226	CbGeAlD
Amantadine—MAOB—testis—hematologic cancer	0.000418	0.0216	CbGeAlD
Amantadine—DRD2—lung—hematologic cancer	0.000374	0.0194	CbGeAlD
Amantadine—DRD2—testis—hematologic cancer	0.000353	0.0183	CbGeAlD
Amantadine—SIGMAR1—lymph node—hematologic cancer	0.000317	0.0164	CbGeAlD
Amantadine—MAOB—lymph node—hematologic cancer	0.000303	0.0157	CbGeAlD
Amantadine—ABCB1—hematopoietic system—hematologic cancer	0.000278	0.0144	CbGeAlD
Amantadine—ABCB1—gonad—hematologic cancer	0.000212	0.011	CbGeAlD
Amantadine—ABCB1—blood—hematologic cancer	0.000184	0.00954	CbGeAlD
Amantadine—ABCB1—bone marrow—hematologic cancer	0.000178	0.00923	CbGeAlD
Amantadine—ABCB1—lung—hematologic cancer	0.000162	0.00837	CbGeAlD
Amantadine—ABCB1—testis—hematologic cancer	0.000153	0.00789	CbGeAlD
Amantadine—ABCB1—lymph node—hematologic cancer	0.000111	0.00572	CbGeAlD
Amantadine—Nausea—Alitretinoin—hematologic cancer	3.17e-05	0.000159	CcSEcCtD
Amantadine—Convulsion—Prednisone—hematologic cancer	3.17e-05	0.000159	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—hematologic cancer	3.17e-05	0.000159	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—hematologic cancer	3.17e-05	0.000159	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—hematologic cancer	3.17e-05	0.000159	CcSEcCtD
Amantadine—Hypertension—Prednisone—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Amantadine—Rash—Mitoxantrone—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Amantadine—Rash—Irinotecan—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Amantadine—Dermatitis—Mitoxantrone—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Amantadine—Dermatitis—Irinotecan—hematologic cancer	3.16e-05	0.000159	CcSEcCtD
Amantadine—Headache—Mitoxantrone—hematologic cancer	3.14e-05	0.000158	CcSEcCtD
Amantadine—Headache—Irinotecan—hematologic cancer	3.14e-05	0.000158	CcSEcCtD
Amantadine—Nausea—Ifosfamide—hematologic cancer	3.14e-05	0.000158	CcSEcCtD
Amantadine—Feeling abnormal—Triamcinolone—hematologic cancer	3.12e-05	0.000157	CcSEcCtD
Amantadine—Diarrhoea—Cisplatin—hematologic cancer	3.12e-05	0.000156	CcSEcCtD
Amantadine—Anxiety—Prednisone—hematologic cancer	3.11e-05	0.000156	CcSEcCtD
Amantadine—Alopecia—Methotrexate—hematologic cancer	3.11e-05	0.000156	CcSEcCtD
Amantadine—Vomiting—Gemcitabine—hematologic cancer	3.11e-05	0.000156	CcSEcCtD
Amantadine—Insomnia—Betamethasone—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Amantadine—Insomnia—Dexamethasone—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.1e-05	0.000156	CcSEcCtD
Amantadine—Paraesthesia—Betamethasone—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Amantadine—Paraesthesia—Dexamethasone—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Amantadine—Rash—Gemcitabine—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Amantadine—Dermatitis—Gemcitabine—hematologic cancer	3.08e-05	0.000155	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—hematologic cancer	3.08e-05	0.000154	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—hematologic cancer	3.07e-05	0.000154	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—hematologic cancer	3.06e-05	0.000154	CcSEcCtD
Amantadine—Headache—Gemcitabine—hematologic cancer	3.06e-05	0.000154	CcSEcCtD
Amantadine—Nausea—Vincristine—hematologic cancer	3.06e-05	0.000154	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—hematologic cancer	3.05e-05	0.000153	CcSEcCtD
Amantadine—Hypersensitivity—Prednisolone—hematologic cancer	3.03e-05	0.000152	CcSEcCtD
Amantadine—Dyspepsia—Betamethasone—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Amantadine—Dyspepsia—Dexamethasone—hematologic cancer	3.02e-05	0.000152	CcSEcCtD
Amantadine—Urinary tract disorder—Doxorubicin—hematologic cancer	3.01e-05	0.000151	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—hematologic cancer	3e-05	0.000151	CcSEcCtD
Amantadine—Asthenia—Etoposide—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Body temperature increased—Triamcinolone—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Anaphylactic shock—Prednisone—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Oedema—Prednisone—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—hematologic cancer	2.99e-05	0.00015	CcSEcCtD
Amantadine—Decreased appetite—Betamethasone—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Amantadine—Decreased appetite—Dexamethasone—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Amantadine—Nausea—Mitoxantrone—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Amantadine—Nausea—Irinotecan—hematologic cancer	2.98e-05	0.00015	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—hematologic cancer	2.97e-05	0.000149	CcSEcCtD
Amantadine—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.96e-05	0.000149	CcSEcCtD
Amantadine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.96e-05	0.000149	CcSEcCtD
Amantadine—Fatigue—Dexamethasone—hematologic cancer	2.96e-05	0.000149	CcSEcCtD
Amantadine—Fatigue—Betamethasone—hematologic cancer	2.96e-05	0.000149	CcSEcCtD
Amantadine—Pruritus—Etoposide—hematologic cancer	2.95e-05	0.000148	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—hematologic cancer	2.94e-05	0.000148	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—hematologic cancer	2.93e-05	0.000147	CcSEcCtD
Amantadine—Nervous system disorder—Prednisone—hematologic cancer	2.93e-05	0.000147	CcSEcCtD
Amantadine—Tachycardia—Prednisone—hematologic cancer	2.92e-05	0.000147	CcSEcCtD
Amantadine—Alopecia—Epirubicin—hematologic cancer	2.91e-05	0.000146	CcSEcCtD
Amantadine—Skin disorder—Prednisone—hematologic cancer	2.9e-05	0.000146	CcSEcCtD
Amantadine—Nausea—Gemcitabine—hematologic cancer	2.9e-05	0.000146	CcSEcCtD
Amantadine—Vomiting—Cisplatin—hematologic cancer	2.89e-05	0.000145	CcSEcCtD
Amantadine—Hyperhidrosis—Prednisone—hematologic cancer	2.89e-05	0.000145	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—hematologic cancer	2.89e-05	0.000145	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—hematologic cancer	2.88e-05	0.000145	CcSEcCtD
Amantadine—Rash—Cisplatin—hematologic cancer	2.87e-05	0.000144	CcSEcCtD
Amantadine—Dermatitis—Cisplatin—hematologic cancer	2.87e-05	0.000144	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—hematologic cancer	2.86e-05	0.000144	CcSEcCtD
Amantadine—Diarrhoea—Etoposide—hematologic cancer	2.85e-05	0.000143	CcSEcCtD
Amantadine—Anorexia—Prednisone—hematologic cancer	2.85e-05	0.000143	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—hematologic cancer	2.85e-05	0.000143	CcSEcCtD
Amantadine—Feeling abnormal—Dexamethasone—hematologic cancer	2.83e-05	0.000142	CcSEcCtD
Amantadine—Feeling abnormal—Betamethasone—hematologic cancer	2.83e-05	0.000142	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—hematologic cancer	2.83e-05	0.000142	CcSEcCtD
Amantadine—Tension—Epirubicin—hematologic cancer	2.81e-05	0.000141	CcSEcCtD
Amantadine—Hypersensitivity—Triamcinolone—hematologic cancer	2.79e-05	0.00014	CcSEcCtD
Amantadine—Nervousness—Epirubicin—hematologic cancer	2.78e-05	0.00014	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—hematologic cancer	2.76e-05	0.000139	CcSEcCtD
Amantadine—Dizziness—Etoposide—hematologic cancer	2.76e-05	0.000139	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—hematologic cancer	2.74e-05	0.000138	CcSEcCtD
Amantadine—Dizziness—Prednisolone—hematologic cancer	2.72e-05	0.000137	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—hematologic cancer	2.72e-05	0.000137	CcSEcCtD
Amantadine—Asthenia—Triamcinolone—hematologic cancer	2.71e-05	0.000136	CcSEcCtD
Amantadine—Body temperature increased—Dexamethasone—hematologic cancer	2.71e-05	0.000136	CcSEcCtD
Amantadine—Body temperature increased—Betamethasone—hematologic cancer	2.71e-05	0.000136	CcSEcCtD
Amantadine—Nausea—Cisplatin—hematologic cancer	2.7e-05	0.000136	CcSEcCtD
Amantadine—Insomnia—Prednisone—hematologic cancer	2.7e-05	0.000136	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—hematologic cancer	2.7e-05	0.000136	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—hematologic cancer	2.69e-05	0.000135	CcSEcCtD
Amantadine—Paraesthesia—Prednisone—hematologic cancer	2.68e-05	0.000135	CcSEcCtD
Amantadine—Pruritus—Triamcinolone—hematologic cancer	2.68e-05	0.000134	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—hematologic cancer	2.67e-05	0.000134	CcSEcCtD
Amantadine—Convulsion—Methotrexate—hematologic cancer	2.65e-05	0.000133	CcSEcCtD
Amantadine—Vomiting—Etoposide—hematologic cancer	2.65e-05	0.000133	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—hematologic cancer	2.65e-05	0.000133	CcSEcCtD
Amantadine—Agitation—Epirubicin—hematologic cancer	2.63e-05	0.000132	CcSEcCtD
Amantadine—Dyspepsia—Prednisone—hematologic cancer	2.63e-05	0.000132	CcSEcCtD
Amantadine—Rash—Etoposide—hematologic cancer	2.63e-05	0.000132	CcSEcCtD
Amantadine—Dermatitis—Etoposide—hematologic cancer	2.63e-05	0.000132	CcSEcCtD
Amantadine—Headache—Etoposide—hematologic cancer	2.61e-05	0.000131	CcSEcCtD
Amantadine—Tension—Doxorubicin—hematologic cancer	2.6e-05	0.000131	CcSEcCtD
Amantadine—Decreased appetite—Prednisone—hematologic cancer	2.6e-05	0.00013	CcSEcCtD
Amantadine—Rash—Prednisolone—hematologic cancer	2.59e-05	0.00013	CcSEcCtD
Amantadine—Dermatitis—Prednisolone—hematologic cancer	2.59e-05	0.00013	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.59e-05	0.00013	CcSEcCtD
Amantadine—Fatigue—Prednisone—hematologic cancer	2.58e-05	0.000129	CcSEcCtD
Amantadine—Headache—Prednisolone—hematologic cancer	2.58e-05	0.000129	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—hematologic cancer	2.57e-05	0.000129	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—hematologic cancer	2.56e-05	0.000129	CcSEcCtD
Amantadine—Constipation—Prednisone—hematologic cancer	2.56e-05	0.000128	CcSEcCtD
Amantadine—Palpitations—Epirubicin—hematologic cancer	2.53e-05	0.000127	CcSEcCtD
Amantadine—Confusional state—Methotrexate—hematologic cancer	2.52e-05	0.000127	CcSEcCtD
Amantadine—Dizziness—Triamcinolone—hematologic cancer	2.5e-05	0.000126	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—hematologic cancer	2.5e-05	0.000125	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—hematologic cancer	2.5e-05	0.000125	CcSEcCtD
Amantadine—Convulsion—Epirubicin—hematologic cancer	2.48e-05	0.000125	CcSEcCtD
Amantadine—Nausea—Etoposide—hematologic cancer	2.48e-05	0.000124	CcSEcCtD
Amantadine—Hypertension—Epirubicin—hematologic cancer	2.47e-05	0.000124	CcSEcCtD
Amantadine—Feeling abnormal—Prednisone—hematologic cancer	2.46e-05	0.000124	CcSEcCtD
Amantadine—Asthenia—Dexamethasone—hematologic cancer	2.46e-05	0.000124	CcSEcCtD
Amantadine—Asthenia—Betamethasone—hematologic cancer	2.46e-05	0.000124	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—hematologic cancer	2.45e-05	0.000123	CcSEcCtD
Amantadine—Nausea—Prednisolone—hematologic cancer	2.44e-05	0.000123	CcSEcCtD
Amantadine—Agitation—Doxorubicin—hematologic cancer	2.44e-05	0.000122	CcSEcCtD
Amantadine—Anxiety—Epirubicin—hematologic cancer	2.43e-05	0.000122	CcSEcCtD
Amantadine—Pruritus—Betamethasone—hematologic cancer	2.43e-05	0.000122	CcSEcCtD
Amantadine—Pruritus—Dexamethasone—hematologic cancer	2.43e-05	0.000122	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—hematologic cancer	2.43e-05	0.000122	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.42e-05	0.000122	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—hematologic cancer	2.42e-05	0.000121	CcSEcCtD
Amantadine—Vomiting—Triamcinolone—hematologic cancer	2.41e-05	0.000121	CcSEcCtD
Amantadine—Rash—Triamcinolone—hematologic cancer	2.39e-05	0.00012	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—hematologic cancer	2.39e-05	0.00012	CcSEcCtD
Amantadine—Dermatitis—Triamcinolone—hematologic cancer	2.38e-05	0.00012	CcSEcCtD
Amantadine—Anorexia—Methotrexate—hematologic cancer	2.38e-05	0.00012	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—hematologic cancer	2.37e-05	0.000119	CcSEcCtD
Amantadine—Headache—Triamcinolone—hematologic cancer	2.37e-05	0.000119	CcSEcCtD
Amantadine—Body temperature increased—Prednisone—hematologic cancer	2.36e-05	0.000119	CcSEcCtD
Amantadine—Confusional state—Epirubicin—hematologic cancer	2.36e-05	0.000118	CcSEcCtD
Amantadine—Diarrhoea—Dexamethasone—hematologic cancer	2.35e-05	0.000118	CcSEcCtD
Amantadine—Diarrhoea—Betamethasone—hematologic cancer	2.35e-05	0.000118	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—hematologic cancer	2.34e-05	0.000118	CcSEcCtD
Amantadine—Oedema—Epirubicin—hematologic cancer	2.34e-05	0.000117	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—hematologic cancer	2.34e-05	0.000117	CcSEcCtD
Amantadine—Hypotension—Methotrexate—hematologic cancer	2.33e-05	0.000117	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—hematologic cancer	2.3e-05	0.000115	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—hematologic cancer	2.29e-05	0.000115	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—hematologic cancer	2.29e-05	0.000115	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—hematologic cancer	2.28e-05	0.000115	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—hematologic cancer	2.27e-05	0.000114	CcSEcCtD
Amantadine—Dizziness—Dexamethasone—hematologic cancer	2.27e-05	0.000114	CcSEcCtD
Amantadine—Dizziness—Betamethasone—hematologic cancer	2.27e-05	0.000114	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—hematologic cancer	2.26e-05	0.000114	CcSEcCtD
Amantadine—Insomnia—Methotrexate—hematologic cancer	2.26e-05	0.000113	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—hematologic cancer	2.25e-05	0.000113	CcSEcCtD
Amantadine—Nausea—Triamcinolone—hematologic cancer	2.25e-05	0.000113	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—hematologic cancer	2.24e-05	0.000113	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.24e-05	0.000113	CcSEcCtD
Amantadine—Anorexia—Epirubicin—hematologic cancer	2.23e-05	0.000112	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—hematologic cancer	2.23e-05	0.000112	CcSEcCtD
Amantadine—Somnolence—Methotrexate—hematologic cancer	2.22e-05	0.000112	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—hematologic cancer	2.21e-05	0.000111	CcSEcCtD
Amantadine—Hypersensitivity—Prednisone—hematologic cancer	2.2e-05	0.000111	CcSEcCtD
Amantadine—Dyspepsia—Methotrexate—hematologic cancer	2.2e-05	0.00011	CcSEcCtD
Amantadine—Hypotension—Epirubicin—hematologic cancer	2.18e-05	0.00011	CcSEcCtD
Amantadine—Vomiting—Betamethasone—hematologic cancer	2.18e-05	0.00011	CcSEcCtD
Amantadine—Vomiting—Dexamethasone—hematologic cancer	2.18e-05	0.00011	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—hematologic cancer	2.18e-05	0.00011	CcSEcCtD
Amantadine—Decreased appetite—Methotrexate—hematologic cancer	2.17e-05	0.000109	CcSEcCtD
Amantadine—Rash—Dexamethasone—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Rash—Betamethasone—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Oedema—Doxorubicin—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Dermatitis—Dexamethasone—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Dermatitis—Betamethasone—hematologic cancer	2.16e-05	0.000109	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.16e-05	0.000108	CcSEcCtD
Amantadine—Fatigue—Methotrexate—hematologic cancer	2.15e-05	0.000108	CcSEcCtD
Amantadine—Headache—Betamethasone—hematologic cancer	2.15e-05	0.000108	CcSEcCtD
Amantadine—Headache—Dexamethasone—hematologic cancer	2.15e-05	0.000108	CcSEcCtD
Amantadine—Asthenia—Prednisone—hematologic cancer	2.14e-05	0.000108	CcSEcCtD
Amantadine—Nervous system disorder—Doxorubicin—hematologic cancer	2.12e-05	0.000107	CcSEcCtD
Amantadine—Pruritus—Prednisone—hematologic cancer	2.12e-05	0.000106	CcSEcCtD
Amantadine—Insomnia—Epirubicin—hematologic cancer	2.11e-05	0.000106	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—hematologic cancer	2.11e-05	0.000106	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—hematologic cancer	2.1e-05	0.000106	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—hematologic cancer	2.1e-05	0.000105	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—hematologic cancer	2.09e-05	0.000105	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—hematologic cancer	2.08e-05	0.000105	CcSEcCtD
Amantadine—Somnolence—Epirubicin—hematologic cancer	2.08e-05	0.000104	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—hematologic cancer	2.06e-05	0.000104	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—hematologic cancer	2.06e-05	0.000103	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—hematologic cancer	2.06e-05	0.000103	CcSEcCtD
Amantadine—Diarrhoea—Prednisone—hematologic cancer	2.05e-05	0.000103	CcSEcCtD
Amantadine—Nausea—Betamethasone—hematologic cancer	2.04e-05	0.000102	CcSEcCtD
Amantadine—Nausea—Dexamethasone—hematologic cancer	2.04e-05	0.000102	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—hematologic cancer	2.03e-05	0.000102	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—hematologic cancer	2.02e-05	0.000102	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.02e-05	0.000101	CcSEcCtD
Amantadine—Fatigue—Epirubicin—hematologic cancer	2.02e-05	0.000101	CcSEcCtD
Amantadine—Constipation—Epirubicin—hematologic cancer	2e-05	0.0001	CcSEcCtD
Amantadine—Dizziness—Prednisone—hematologic cancer	1.98e-05	9.93e-05	CcSEcCtD
Amantadine—Body temperature increased—Methotrexate—hematologic cancer	1.98e-05	9.92e-05	CcSEcCtD
Amantadine—Insomnia—Doxorubicin—hematologic cancer	1.96e-05	9.83e-05	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—hematologic cancer	1.94e-05	9.75e-05	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—hematologic cancer	1.93e-05	9.69e-05	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—hematologic cancer	1.93e-05	9.68e-05	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—hematologic cancer	1.92e-05	9.66e-05	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—hematologic cancer	1.9e-05	9.56e-05	CcSEcCtD
Amantadine—Vomiting—Prednisone—hematologic cancer	1.9e-05	9.54e-05	CcSEcCtD
Amantadine—Rash—Prednisone—hematologic cancer	1.88e-05	9.47e-05	CcSEcCtD
Amantadine—Dermatitis—Prednisone—hematologic cancer	1.88e-05	9.46e-05	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—hematologic cancer	1.88e-05	9.44e-05	CcSEcCtD
Amantadine—Headache—Prednisone—hematologic cancer	1.87e-05	9.4e-05	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.87e-05	9.38e-05	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—hematologic cancer	1.87e-05	9.37e-05	CcSEcCtD
Amantadine—Constipation—Doxorubicin—hematologic cancer	1.85e-05	9.29e-05	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—hematologic cancer	1.85e-05	9.28e-05	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—hematologic cancer	1.84e-05	9.24e-05	CcSEcCtD
Amantadine—Asthenia—Methotrexate—hematologic cancer	1.79e-05	9e-05	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—hematologic cancer	1.78e-05	8.95e-05	CcSEcCtD
Amantadine—Nausea—Prednisone—hematologic cancer	1.78e-05	8.92e-05	CcSEcCtD
Amantadine—Pruritus—Methotrexate—hematologic cancer	1.77e-05	8.88e-05	CcSEcCtD
Amantadine—Hypersensitivity—Epirubicin—hematologic cancer	1.72e-05	8.65e-05	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—hematologic cancer	1.71e-05	8.59e-05	CcSEcCtD
Amantadine—Diarrhoea—Methotrexate—hematologic cancer	1.71e-05	8.58e-05	CcSEcCtD
Amantadine—Asthenia—Epirubicin—hematologic cancer	1.68e-05	8.42e-05	CcSEcCtD
Amantadine—Pruritus—Epirubicin—hematologic cancer	1.65e-05	8.31e-05	CcSEcCtD
Amantadine—Dizziness—Methotrexate—hematologic cancer	1.65e-05	8.3e-05	CcSEcCtD
Amantadine—Diarrhoea—Epirubicin—hematologic cancer	1.6e-05	8.03e-05	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—hematologic cancer	1.59e-05	8e-05	CcSEcCtD
Amantadine—Vomiting—Methotrexate—hematologic cancer	1.59e-05	7.98e-05	CcSEcCtD
Amantadine—Rash—Methotrexate—hematologic cancer	1.58e-05	7.91e-05	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—hematologic cancer	1.57e-05	7.9e-05	CcSEcCtD
Amantadine—Headache—Methotrexate—hematologic cancer	1.57e-05	7.86e-05	CcSEcCtD
Amantadine—Asthenia—Doxorubicin—hematologic cancer	1.55e-05	7.79e-05	CcSEcCtD
Amantadine—Dizziness—Epirubicin—hematologic cancer	1.55e-05	7.76e-05	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—hematologic cancer	1.53e-05	7.69e-05	CcSEcCtD
Amantadine—Vomiting—Epirubicin—hematologic cancer	1.49e-05	7.47e-05	CcSEcCtD
Amantadine—Nausea—Methotrexate—hematologic cancer	1.48e-05	7.45e-05	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—hematologic cancer	1.48e-05	7.43e-05	CcSEcCtD
Amantadine—Rash—Epirubicin—hematologic cancer	1.47e-05	7.4e-05	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—hematologic cancer	1.47e-05	7.4e-05	CcSEcCtD
Amantadine—Headache—Epirubicin—hematologic cancer	1.46e-05	7.36e-05	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—hematologic cancer	1.43e-05	7.18e-05	CcSEcCtD
Amantadine—Nausea—Epirubicin—hematologic cancer	1.39e-05	6.97e-05	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—hematologic cancer	1.38e-05	6.91e-05	CcSEcCtD
Amantadine—Rash—Doxorubicin—hematologic cancer	1.36e-05	6.85e-05	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—hematologic cancer	1.36e-05	6.84e-05	CcSEcCtD
Amantadine—Headache—Doxorubicin—hematologic cancer	1.36e-05	6.81e-05	CcSEcCtD
Amantadine—Nausea—Doxorubicin—hematologic cancer	1.29e-05	6.45e-05	CcSEcCtD
Amantadine—MAOB—Metabolism—PIK3CG—hematologic cancer	6.36e-06	6.42e-05	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—hematologic cancer	6.36e-06	6.42e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GRB2—hematologic cancer	6.28e-06	6.34e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3R1—hematologic cancer	6.27e-06	6.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	6.26e-06	6.32e-05	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ALB—hematologic cancer	6.25e-06	6.31e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AGRN—hematologic cancer	6.23e-06	6.3e-05	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—hematologic cancer	6.23e-06	6.29e-05	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	6.22e-06	6.29e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CSF2—hematologic cancer	6.18e-06	6.24e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	6.09e-06	6.14e-05	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—hematologic cancer	6.07e-06	6.13e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDE4B—hematologic cancer	6.05e-06	6.11e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CNR2—hematologic cancer	6.05e-06	6.11e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF19—hematologic cancer	6e-06	6.06e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—JAK1—hematologic cancer	5.96e-06	6.02e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PRKCG—hematologic cancer	5.96e-06	6.02e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RAC2—hematologic cancer	5.95e-06	6.01e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CD44—hematologic cancer	5.93e-06	5.99e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NQO1—hematologic cancer	5.93e-06	5.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	5.93e-06	5.98e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HMMR—hematologic cancer	5.91e-06	5.97e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IDH2—hematologic cancer	5.91e-06	5.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—DKK1—hematologic cancer	5.91e-06	5.96e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CREBBP—hematologic cancer	5.89e-06	5.95e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT5B—hematologic cancer	5.86e-06	5.92e-05	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ALB—hematologic cancer	5.83e-06	5.88e-05	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—hematologic cancer	5.79e-06	5.85e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CB—hematologic cancer	5.79e-06	5.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADCY7—hematologic cancer	5.69e-06	5.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CSF2—hematologic cancer	5.61e-06	5.67e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYCS—hematologic cancer	5.61e-06	5.66e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	5.61e-06	5.66e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CD—hematologic cancer	5.59e-06	5.64e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HSP90AA1—hematologic cancer	5.57e-06	5.63e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2RA—hematologic cancer	5.57e-06	5.62e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ARNTL—hematologic cancer	5.56e-06	5.61e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—XIAP—hematologic cancer	5.53e-06	5.59e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NQO1—hematologic cancer	5.53e-06	5.58e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CD44—hematologic cancer	5.53e-06	5.58e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALB—hematologic cancer	5.52e-06	5.57e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	5.45e-06	5.51e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	5.44e-06	5.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—JAK1—hematologic cancer	5.42e-06	5.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PRKCG—hematologic cancer	5.42e-06	5.47e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ACP5—hematologic cancer	5.41e-06	5.46e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CA9—hematologic cancer	5.41e-06	5.46e-05	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—hematologic cancer	5.4e-06	5.45e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SH2B3—hematologic cancer	5.39e-06	5.45e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMARCA4—hematologic cancer	5.39e-06	5.45e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GZMB—hematologic cancer	5.36e-06	5.41e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOR2—hematologic cancer	5.34e-06	5.39e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3R1—hematologic cancer	5.28e-06	5.33e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNA1—hematologic cancer	5.23e-06	5.28e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYCS—hematologic cancer	5.23e-06	5.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EIF4EBP1—hematologic cancer	5.2e-06	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HSPB1—hematologic cancer	5.2e-06	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL3—hematologic cancer	5.2e-06	5.25e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HSP90AA1—hematologic cancer	5.19e-06	5.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SDC1—hematologic cancer	5.14e-06	5.19e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTHLH—hematologic cancer	5.14e-06	5.19e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—IDH1—hematologic cancer	5.08e-06	5.13e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	5.08e-06	5.13e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2RA—hematologic cancer	5.06e-06	5.11e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	5.04e-06	5.09e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCC3—hematologic cancer	5.03e-06	5.07e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TXN—hematologic cancer	5.03e-06	5.07e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTO1—hematologic cancer	5.03e-06	5.07e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTGER4—hematologic cancer	5.01e-06	5.06e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—hematologic cancer	5e-06	5.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LCK—hematologic cancer	4.98e-06	5.03e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTP1—hematologic cancer	4.94e-06	4.99e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SPHK1—hematologic cancer	4.92e-06	4.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—H3F3A—hematologic cancer	4.88e-06	4.93e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CB—hematologic cancer	4.87e-06	4.92e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—hematologic cancer	4.77e-06	4.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCZ—hematologic cancer	4.75e-06	4.79e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—UGT1A1—hematologic cancer	4.72e-06	4.77e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—hematologic cancer	4.68e-06	4.73e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—hematologic cancer	4.64e-06	4.69e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	4.63e-06	4.67e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTP1—hematologic cancer	4.61e-06	4.65e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC22A1—hematologic cancer	4.6e-06	4.64e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CRABP1—hematologic cancer	4.6e-06	4.64e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PARP1—hematologic cancer	4.59e-06	4.63e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTM1—hematologic cancer	4.54e-06	4.59e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NCOR1—hematologic cancer	4.54e-06	4.59e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FBXW7—hematologic cancer	4.51e-06	4.56e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALOX5—hematologic cancer	4.48e-06	4.52e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	4.48e-06	4.52e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HDAC2—hematologic cancer	4.42e-06	4.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR4—hematologic cancer	4.42e-06	4.47e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—hematologic cancer	4.36e-06	4.4e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NUP98—hematologic cancer	4.34e-06	4.38e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CBL—hematologic cancer	4.31e-06	4.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL3—hematologic cancer	4.27e-06	4.31e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTM1—hematologic cancer	4.23e-06	4.28e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NCOR1—hematologic cancer	4.23e-06	4.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—hematologic cancer	4.21e-06	4.26e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ADCY7—hematologic cancer	4.21e-06	4.25e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOA3—hematologic cancer	4.21e-06	4.25e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—hematologic cancer	4.21e-06	4.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTPN1—hematologic cancer	4.19e-06	4.23e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NUP214—hematologic cancer	4.18e-06	4.22e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTPN11—hematologic cancer	4.14e-06	4.18e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RASGRP1—hematologic cancer	4.13e-06	4.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SYK—hematologic cancer	4.11e-06	4.15e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HSP90AA1—hematologic cancer	4.11e-06	4.15e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTR—hematologic cancer	4.1e-06	4.14e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCG2—hematologic cancer	4.1e-06	4.14e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CD—hematologic cancer	4.08e-06	4.12e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO2—hematologic cancer	4.02e-06	4.06e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—hematologic cancer	4.02e-06	4.05e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—hematologic cancer	4.01e-06	4.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CREB1—hematologic cancer	4.01e-06	4.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT1—hematologic cancer	3.97e-06	4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL2—hematologic cancer	3.93e-06	3.96e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6R—hematologic cancer	3.91e-06	3.95e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTT1—hematologic cancer	3.9e-06	3.93e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3R1—hematologic cancer	3.85e-06	3.89e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SDC1—hematologic cancer	3.81e-06	3.85e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	3.78e-06	3.82e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—JAK2—hematologic cancer	3.74e-06	3.78e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—hematologic cancer	3.74e-06	3.78e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAP2K1—hematologic cancer	3.73e-06	3.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GRB2—hematologic cancer	3.71e-06	3.75e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CD—hematologic cancer	3.7e-06	3.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFA—hematologic cancer	3.7e-06	3.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KITLG—hematologic cancer	3.65e-06	3.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.65e-06	3.68e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT5A—hematologic cancer	3.57e-06	3.6e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CB—hematologic cancer	3.56e-06	3.59e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN2B—hematologic cancer	3.53e-06	3.57e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—hematologic cancer	3.53e-06	3.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3R1—hematologic cancer	3.5e-06	3.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD86—hematologic cancer	3.42e-06	3.45e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.41e-06	3.45e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—JAK2—hematologic cancer	3.4e-06	3.43e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—hematologic cancer	3.37e-06	3.41e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HES1—hematologic cancer	3.37e-06	3.4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NCOR1—hematologic cancer	3.35e-06	3.39e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CSF2—hematologic cancer	3.32e-06	3.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF1—hematologic cancer	3.32e-06	3.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FOXO1—hematologic cancer	3.27e-06	3.3e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—hematologic cancer	3.27e-06	3.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRB—hematologic cancer	3.26e-06	3.29e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CD44—hematologic cancer	3.24e-06	3.27e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NQO1—hematologic cancer	3.24e-06	3.27e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CB—hematologic cancer	3.23e-06	3.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRA—hematologic cancer	3.21e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAK1—hematologic cancer	3.2e-06	3.23e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCG—hematologic cancer	3.2e-06	3.23e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—hematologic cancer	3.14e-06	3.18e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CREBBP—hematologic cancer	3.13e-06	3.16e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYCS—hematologic cancer	3.06e-06	3.09e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.04e-06	3.07e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2RA—hematologic cancer	2.99e-06	3.02e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—hematologic cancer	2.97e-06	3e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CD—hematologic cancer	2.97e-06	2.99e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—hematologic cancer	2.97e-06	2.99e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—hematologic cancer	2.95e-06	2.98e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALB—hematologic cancer	2.93e-06	2.96e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CREBBP—hematologic cancer	2.92e-06	2.94e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFB—hematologic cancer	2.88e-06	2.91e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—hematologic cancer	2.88e-06	2.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TSC2—hematologic cancer	2.82e-06	2.85e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3R1—hematologic cancer	2.8e-06	2.83e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CD—hematologic cancer	2.76e-06	2.79e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALB—hematologic cancer	2.73e-06	2.76e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR3—hematologic cancer	2.71e-06	2.74e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTP1—hematologic cancer	2.7e-06	2.73e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK14—hematologic cancer	2.68e-06	2.71e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—hematologic cancer	2.63e-06	2.66e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3R1—hematologic cancer	2.61e-06	2.64e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FN1—hematologic cancer	2.6e-06	2.63e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CB—hematologic cancer	2.58e-06	2.61e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NFKBIA—hematologic cancer	2.57e-06	2.6e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BAD—hematologic cancer	2.57e-06	2.6e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH1—hematologic cancer	2.55e-06	2.57e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD80—hematologic cancer	2.49e-06	2.52e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—hematologic cancer	2.49e-06	2.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KIT—hematologic cancer	2.49e-06	2.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—hematologic cancer	2.49e-06	2.51e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTM1—hematologic cancer	2.48e-06	2.51e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOR1—hematologic cancer	2.48e-06	2.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTPN11—hematologic cancer	2.45e-06	2.47e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—hematologic cancer	2.43e-06	2.45e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CB—hematologic cancer	2.41e-06	2.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK3—hematologic cancer	2.38e-06	2.41e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREB1—hematologic cancer	2.37e-06	2.39e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BRAF—hematologic cancer	2.34e-06	2.36e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL2—hematologic cancer	2.32e-06	2.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6R—hematologic cancer	2.31e-06	2.33e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREBBP—hematologic cancer	2.31e-06	2.33e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—hematologic cancer	2.23e-06	2.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	2.2e-06	2.22e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.19e-06	2.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	2.19e-06	2.21e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.17e-06	2.19e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—hematologic cancer	2.14e-06	2.16e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—hematologic cancer	2.13e-06	2.15e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF2—hematologic cancer	2.1e-06	2.12e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—hematologic cancer	2.08e-06	2.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	2.07e-06	2.09e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAK2—hematologic cancer	2.01e-06	2.03e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—hematologic cancer	1.99e-06	2e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	1.97e-06	1.99e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—hematologic cancer	1.96e-06	1.98e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MTOR—hematologic cancer	1.91e-06	1.93e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	1.91e-06	1.93e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.84e-06	1.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—hematologic cancer	1.82e-06	1.84e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	1.79e-06	1.81e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	1.77e-06	1.79e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—hematologic cancer	1.75e-06	1.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—hematologic cancer	1.75e-06	1.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—hematologic cancer	1.74e-06	1.76e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CREBBP—hematologic cancer	1.71e-06	1.73e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—hematologic cancer	1.71e-06	1.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JUN—hematologic cancer	1.7e-06	1.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	1.65e-06	1.67e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—hematologic cancer	1.65e-06	1.66e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.62e-06	1.64e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK8—hematologic cancer	1.61e-06	1.63e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—hematologic cancer	1.61e-06	1.62e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALB—hematologic cancer	1.6e-06	1.61e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—hematologic cancer	1.58e-06	1.59e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—hematologic cancer	1.57e-06	1.59e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.53e-06	1.54e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SRC—hematologic cancer	1.53e-06	1.54e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—hematologic cancer	1.49e-06	1.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—hematologic cancer	1.47e-06	1.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—hematologic cancer	1.47e-06	1.48e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—hematologic cancer	1.47e-06	1.48e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.41e-06	1.43e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK3—hematologic cancer	1.41e-06	1.42e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—hematologic cancer	1.37e-06	1.38e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—hematologic cancer	1.37e-06	1.38e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—hematologic cancer	1.29e-06	1.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—hematologic cancer	1.27e-06	1.28e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—hematologic cancer	1.22e-06	1.23e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—hematologic cancer	1.2e-06	1.21e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—hematologic cancer	1.16e-06	1.18e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.16e-06	1.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—hematologic cancer	1.12e-06	1.14e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.08e-06	1.09e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—hematologic cancer	1.03e-06	1.04e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—hematologic cancer	9.5e-07	9.59e-06	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—hematologic cancer	8.61e-07	8.69e-06	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—hematologic cancer	7.03e-07	7.1e-06	CbGpPWpGaD
